Polymer therapeutics has gained prominence due to an attractive structural polymer chemistry and its applications in diseases therapy. In this review, we discussed the development and capabilities of N-(2-hydroxypropyl) methacrylamide (HPMA) and HPMA–drug conjugates in cancer therapy. The design, architecture, and structural properties of HPMA make it a versatile system for the synthesis of polymeric conjugations for biomedical applications. Research suggests that HPMA could be a possible alternative for polymers such polyethylene glycol (PEG) in biomedical applications. Although numerous clinical trials of HPMA–drug conjugates are ongoing, yet no product has been successfully brought to the market. Thus, further research is required to develop HPMA–drug conjugates as successful cancer therapeutics.

由于有吸引力的结构聚合物化学及其在疾病治疗中的应用，聚合物疗法已获得突出地位。在这篇综述中，我们讨论了N- (2-羟丙基) 甲基丙烯酰胺 (HPMA) 和 HPMA 药物偶联物在癌症治疗中的发展和能力。HPMA 的设计、结构和结构特性使其成为用于合成生物医学应用的聚合物偶联物的通用系统。研究表明，HPMA 可能是生物医学应用中聚乙二醇 (PEG) 等聚合物的可能替代品。尽管 HPMA 药物偶联物的大量临床试验正在进行中，但还没有产品成功推向市场。因此，需要进一步研究以开发 HPMA-药物偶联物作为成功的癌症治疗剂。